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Purpose: Although the prognosis of patients with pT1a stage renal cell carcinoma (RCC) 
is generally good, some of these patients show distant metastasis. In this study, we in-
tended to identify the perioperative and pathologic prognostic factors for patients with 
pT1a stage RCC.
Materials and Methods: A total of 93 patients who were diagnosed with pT1aN0M0 
RCC between January 1995 and December 2004 were included. All the patients under-
went radical (n=63, 67.7%) or partial (n=30, 32.3%) nephrectomy by a single surgeon. 
Preoperative data [age, sex, body mass index (BMI), and the presence of symptoms], 
follow-up duration, surgical methods, and pathological parameters (tumor size, tumor 
location, histologic type, Fuhrman’s nuclear grade and the presence of microvascular 
invasion, hemorrhage, necrosis, calcification, and a cystic component in the tumor) 
were retrospectively analyzed to identify which of these were prognostic factors for pT1a 
RCC.
Results: The patients’ mean age was 55.0±11.4 years and the mean follow-up duration 
was 63.6±31.1 months. The 5-year cancer-specific survival rate and the 5-year re-
currence-free survival rate were 100% and 88.1%, respectively. Nine patients (9.7%) 
showed distant metastasis, but local recurrence was not shown. Fuhrman’s nuclear 
grade (p=0.040, OR=5.147), microvascular invasion (p=0.011, OR=13.500), and tumor 
necrosis (p＜0.001, OR=26.000) had a significant impact on distant metastasis in the 
univariate analysis. The multivariate analysis subsequently showed that micro-
vascular invasion (p=0.033, OR=17.947) and tumor necrosis (p=0.002, OR=15.922) 
were independent prognostic factors.
Conclusions: Microvascular invasion and tumor necrosis are the prognostic factors for 
patients with pT1a RCC. 
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INTRODUCTION
The proportion of renal cell carcinoma (RCC) that is diagnosed 
as pT1a is known to have recently increased [1]. Advances 
in diagnostic imaging, such as ultrasonography (USG), 
computed tomography (CT), and magnetic resonance imaging, 
have led to an increased incidence of finding small-sized re-
nal tumors [1,2]. Although patients with pT1a RCC gen-
erally have a good prognosis, some patients who have un-
dergone nephron-sparing surgery or radical nephrectomy 
show a local relapse at the previous surgical site or distant 
metastasis [3]. Several clinical, anatomical, histological, 
and immunohistochemical features have been suggested 
to be prognostic factors for disease progression and survival 
[4], but most of the proposed prognostic factors are based 
mainly on the data for large-sized RCCs. Unfortunately, 
the ability to predict the biological potential of small RCCs 
remains limited, and so patient counseling and clinical de-
cision making remain suboptimal. Dall’Oglio et al reported 
that RCC is a singular disease with a highly variable natu-
ral history and that identifying a reliable set of prognostic 
factors may improve the treatment of patients with this dis-
ease [4]. Therefore, it is important to define the prognostic 
factors of small RCC. In this study, we intended to identify 
the perioperative and pathologic prognostic factors for pa-
tients with pT1a stage RCC.Korean J Urol 2010;51:233-238
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TABLE 1. The characteristics of 93 patients with pT1a renal cell 
carcinoma
Characteristics
No. of patients 
(%)
Mean age (years)±SD
Sex
  Male
  Female
Mean BMI (kg/m
2)±SD
Preoperative symptoms
  Flank pain
  Abdominal discomfort
  Weight loss
Follow-up duration (months)
Surgical methods
  Radical nephrectomy
  Partial nephrectomy
Tumor size (cm)
Tumor location
  Upper pole
  Mid pole
  Lower pole
Histologic type
  Clear cell
  Papillary
  Chromophobe
Fuhrman's nuclear grade
  Grade 1 or 2
  Grade 3 or 4
Capsule invasion
Microvascular invasion
Hemorrhage in tumor
Necrosis in tumor
Calcification in tumor
Cystic component in tumor
55.0±11.4
64 (68.8)
29 (31.2)
23.3±3.1
 
7 (7.5)
2 (2.2)
1 (1.1)
63.6±31.1 (10-159)
 
63 (67.7)
30 (32.3)
2.9±0.8 (1.1-4.0)
 
38 (40.9)
34 (36.5)
21 (22.6)
 
79 (85.0)
11 (11.8)
3 (3.2)
 
52 (55.9)
41 (44.1)
8 (8.6)
6 (6.5)
42 (45.2)
12 (13.0)
4 (4.3)
23 (24.7)
BMI: body mass index
FIG. 1. The 5-year cancer-specific survival (A) and the 5-year recurrence-free survival (B) for all the patients with pT1a renal cell 
carcinoma. The statistical analysis: (A) Life-table method, (B) Kaplan-Meier survival analysis.
MATERIALS AND METHODS
1. Patients
A total of 93 patients who were diagnosed with pT1aN0M0 
RCC between January 1995 and December 2004 were in-
cluded in this study. All of the patients underwent radical 
or partial nephrectomy by an experienced surgeon. Among 
the patients, 63 patients (67.7%) underwent radical neph-
rectomy and 30 patients (32.3%) underwent partial neph-
rectomy.
2. Preoperative and postoperative evaluations 
The preoperative evaluations consisted of assessing the 
age, sex, and body mass index (BMI) of the patient and the 
presence of symptoms. The postoperative evaluations con-
sisted of assessing the surgical methods and pathologic pa-
rameters (tumor size, tumor location, histologic type, Fuhr-
man’s nuclear grade and the presence of capsule invasion, 
microvascular invasion, hemorrhage, necrosis, calcifica-
tion, and a cystic component in the tumor). The pathologic 
parameters were evaluated by an experienced pathologist.
3. Follow-up evaluations
All the patients received a follow-up visit at 1 to 2 weeks 
after discharge for assessing their general health status. 
After the first visit, the patients received follow-up evalua-
tions at every 3 or 6 months for the first year and then 
annually. At these times, they were evaluated for newly de-
veloped symptoms and they underwent careful physical ex-
aminations, laboratory tests, and radiologic tests (chest 
X-ray, USG, CT). The USG or CT was evaluated for local 
recurrence or distant metastasis.
4. Definition
The stage was reassessed according to the 2002 TNM clas-
sification system [5]. The RCC histologic type was classi-
fied according to the current WHO classification system 
[6].Korean J Urol 2010;51:233-238
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TABLE 2. Local recurrence and distant metastasis in the patients 
with pT1a renal cell carcinoma
No. of patients (%)
(n=93)
Local recurrence
Distant metastasis
  Lung
  Liver
  Bone
  Brain
  Kidney (contralateral site)
0 (0)
9 (9.7)
4 (4.3)
2 (2.1)
1 (1.1)
1 (1.1)
1 (1.1)
TABLE 3. Univariate analysis of the prognostic factors for distant 
metastasis in the patients with pT1a renal cell carcinoma
Meta-
stasis (n)
No meta-
stasis (n)
p-
value
a
Odds 
ratio
Age (years)
  ≤60 3 57 0.064   4.222
  ＞60 6 27
Sex
  Male 5 59 0.453   1.888
  Female 4 25
BMI (kg/m
2)
  ＜23 5 48 1.000   1.067
  ≥23 4 36
Preoperative symptoms
  Absence 8 75 1.000   1.042
  Presence 1 9
Surgical methods
  Radical nephrectomy 9 54 0.054   0.643
  Partial nephrectomy 0 30
Tumor size (cm)
  ＜3 2 40 0.177   3.182
  ≥37 4 4
Tumor location
  Upper pole 3 35 0.743 -
  Mid pole 3 31
  Lower pole 3 18
Histologic type
  Clear cell 8 71 0.222 -
  Papillary 0 11
  Chromophobe 1 2
Fuhrman's nuclear
 grade
  Grade 1 or 2 2 50 0.040   5.147
  Grade 3 or 4 7 34
Capsule invasion
  Absence 7 78 0.172   3.714
  Presence 2 6
Microvascular invasion
  Absence 6 81 0.011 13.500
  Presence 3 3
Hemorrhage in tumor
  Absence 6 45 0.506   0.577
  Presence 3 39
Necrosis in tumor
  Absence 3 78 ＜0.001 26.000
  Presence 6 6
Calcification in tumor
  Absence 9 80 1.000   0.952
  Presence 0 4
Cystic component in
 tumor
  Absence 9 61 0.106   0.726
  Presence 0 23
BMI: body mass index, 
a: Fisher’s exact test
5. Analysis
The preoperative and postoperative factors were statisti-
cally analyzed together with the presence of local recurrence 
or distant metastasis to identify the prognostic factors for 
patients with pT1a RCC. Univariate analysis was per-
formed by using Fisher’s exact test and the chi-square test. 
Multivariate logistic regression analysis was used to de-
termine the independent prognostic factors affecting local 
recurrence or distant metastasis. Kaplan- Meier survival 
analysis and the life-table method were used to determine 
the 5-year cancer-specific survival rate and the 5-year re-
currence-free survival rate. A 5% level of significance was 
used for all statistical testing, and all statistical tests were 
two-sided. The analysis was performed by using the stat-
istical software SPSS (17.0KO for Windows, Release 
14.0.2; SPSS Inc, Chicago, IL, USA).
RESULTS
The patients’ mean age was 55.0±11.4 years, and of the 93 
patients, 64 (68.8%) were men and 29 (31.2%) were women. 
The characteristics of the 93 patients with pT1a RCC are 
shown in Table 1. The 5-year cancer-specific survival rate 
and the 5-year recurrence-free survival rate were 100% 
and 88.1%, respectively (Fig. 1). 
　Nine patients (9.7%) showed distant metastasis and 
none showed local recurrence at a previous surgical site. 
Among the 9 cases with distant metastasis, the lung (4.3%) 
was the predominant metastatic site. Distant metastasis 
also occurred in the liver (2.1%), bone (1.1%), brain (1.1%), 
and contralateral kidney (1.1%) (Table 2).
　Among all the investigated prognostic factors, Fuhr-
man’s nuclear grade (p=0.040, OR=5.147), microvascular 
invasion (p=0.011, OR=13.500), and tumor necrosis (p＜ 
0.001, OR=26.000) had a significant impact on distant 
metastasis in the univariate analysis. Other factors such 
as age, sex, BMI, preoperative symptoms, surgical methods, 
tumor size, tumor location, histologic type, and the pres-
ence of capsule invasion, hemorrhage, calcification, and a 
cystic component in the tumor were statistically insigni-
ficant. Among the 9 patients with distant metastasis, 3 pa-
tients (33.3%) showed microvascular invasion and 6 pa-
tients (66.7%) showed tumor necrosis. The presence of mi-
crovascular invasion and tumor necrosis showed distant 
metastasis in 50% of the cases, respectively (Table 3).
　Multivariate analysis subsequently showed that micro-
vascular invasion (p=0.033, OR=17.947) and tumor ne-Korean J Urol 2010;51:233-238
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TABLE 4. Local recurrence and distant metastasis in the patients 
with pT1a renal cell carcinoma
Odds 
ratio
95% confidence
interval p-value
a
Lower Upper
Fuhrman's nuclear grade
Microvascular invasion
Necrosis in tumor
9.942
17.947
15.922
0.815
1.261
2.735
121.308
255.376
92.699
0.072
0.033
0.002
a: logistic regression analysis
FIG. 2. Kaplan-Meier survival curve estimates of the 5-year recurrence-free survival for all patients according to (A) microvascular 
invasion and (B) tumor necrosis.
crosis (p=0.002, OR=15.922) were independent factors that 
had an impact on distant metastasis (Table 4). The survival 
rate of the patients with microvascular invasion was sig-
nificantly lower than that of the patients without micro-
vascular invasion (p＜0.001). The survival rate of the pa-
tients with tumor necrosis was also significantly lower 
than that of the patients without tumor necrosis (p＜0.001) 
(Fig. 2).
DISCUSSION
The incidence of RCC has increased in the past decades, 
with the greatest increase being patients with small renal 
tumors. This has led to a migration of RCC cases toward 
earlier stages, and the incidence of RCC continues to grow 
about 3% annually [7]. The widespread use and develop-
ment of radiologic imaging techniques has increased the 
detection of incidental small RCCs.
　Various prognostic factors for RCC such as symptoms, 
tumor size, histologic type, Fuhrman’s nuclear grade, tu-
mor stage, the presence of lymph node metastasis, and the 
presence of tumor necrosis have been evaluated in numer-
ous reports [8,9]. The prognostic value of histopathological 
factors such as tumor stage and grade has been most fre-
quently reevaluated, and these are considered to be the 
most important prognostic factors [8]. But for many cases, 
tumor stage and grade only are not sufficient to predict the 
clinical features [10,11]. Therefore, it is of clinical sig-
nificance to find other prognostic factors that can predict 
the clinical features of RCC. In this study, Fuhrman’s nu-
clear grade, microvascular invasion, and tumor necrosis 
were the significant factors that predicted distant meta-
stasis. Of these, microvascular invasion and tumor ne-
crosis were the independent prognostic factors.
　The molecular behavior and progression of RCC, as well 
as the evaluation of the clinical and pathological predictive 
factors, have recently led to the suggestion of new algo-
rithms to define the prognosis of patients with RCC [12]. 
In addition to the well established prognostic factors such 
as the TNM stage, tumor size, and Fuhrman’s nuclear 
grade [8], the presence of microvascular tumor invasion 
and tumor necrosis in RCC are considered to be important 
predictors of disease progression and recurrence [13-20]. 
Nevertheless, pathological reports of microvascular in-
vasion and tumor necrosis in renal cancer are still not com-
mon in the Korean or international medical literature. 
　Angiogenesis has an essential role in pathological con-
ditions such as RCC, and angiogenic factors are critical for 
the initiation and maintenance of the vascular network. 
Malignant cells perpetually stimulate the host’s stromal 
and vascular cells towards physiological invasion. In the 
same microenvironment, vascular sprouts migrate and in-
vade toward the tumor while the tumor cells migrate out-
ward in the opposite direction. It is known that vascular 
endothelial growth factor (VEGF) stimulates vascular per-
meability along with intravascular growth and neoplastic 
cell invasion. It is well known that RCC is characterized 
by abundant neovascularization, and metastases have 
been more frequently found in patients with highly vascu-
larized primary RCC [21]. Microvascular invasion is ex-
plained by the existence of tumor cells in the walls of the 
microvessels, along with endothelial cells that are locally 
damaged due to the tumor cells [13,16].
　Dall’Oglio et al showed that microvascular invasion is an Korean J Urol 2010;51:233-238
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important independent risk factor for disease-free survival 
(87% vs. 27%) and cancer-specific survival (88% vs. 40%) 
for patients with surgically treated RCC who are negative 
or positive for microvascular invasion, respectively [12]. 
Van Poppel et al reported a 39% rate of disease progression 
for tumors with microvascular invasion, whereas only 6% 
of patients with no microvascular invasion had progression 
[15]. Mrstik et al reported 5-year survival rates of 35% for 
patients with microvascular invasion and 90% for the re-
maining patients [14]. In another study, Dekel et al re-
ported similar findings, with disease progression rates of 
55.5% for patients with microvascular invasion [17]. 
　Tumor necrosis was initially recognized in the 1970s as 
a predictor of aggressive RCC behavior [22]. Various stud-
ies have tried to evaluate the prognostic relevance of tumor 
necrosis as related to disease-free survival and cancer-spe-
cific survival, and some investigations have reported a sig-
nificant influence of tumor necrosis on the survival of RCC 
patients. Han et al reported a 5-year survival rate of 72.2% 
for stage pT1a patients with tumor necrosis and 93.6% for 
stage pT1a patients without tumor necrosis [19]. In anoth-
er study, RCC patients without tumor necrosis showed a 
2 to 3 times higher survival rate than that of the patients 
with tumor necrosis [23,24]. 
　In this study, the presence of microvascular invasion and 
tumor necrosis in the pT1a RCC patients showed a 50% rate 
of distant metastasis, respectively. This showed that these 
factors should not be overlooked in pT1a RCC patients. 
Although this is a retrospective study, it focused on a homo-
geneous group of patients with pT1a RCC and the results 
were strengthened by the fact that all the pathological 
slides were reviewed by an experienced pathologist. Tumor 
size, grade, and stage are generally accepted to be prog-
nostic factors, but several studies have reported that these 
factors had no effect on patients with low stage, small RCC 
[25,26]. In this study, there was no correlation between 
these features and distant metastasis.
　Our study indicates that only 2 pathological features, mi-
crovascular invasion and tumor necrosis, are strong and in-
dependent predictors of distant metastasis. Microvascular 
invasion and tumor necrosis in patients with pT1a RCC 
who are undergoing surgery suggest they have more ag-
gressive disease, and this calls for a closer follow-up. 
CONCLUSIONS
In this study, microvascular invasion and tumor necrosis 
were the prognostic factors in patients with pT1a RCC. 
Classifying and evaluating patients on the basis of these 
pathological features may result in individualized fol-
low-up schedules and better treatment for patients with 
pT1a RCC.
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